ACR-FDA Summit

Program Information

The 2022 summit addressed patient care, policy, and research-relevant topics on the assessment of long-term safety, clinical efficacy, and structural outcomes in conjunction with novel study designs and biomarkers development in the field of rheumatoid arthritis and psoriatic arthritis.

Conducting clinical trials in these areas has become complex and challenging because prolonged placebo use is no longer appropriate or acceptable control to the community and patients. Respectively, stakeholders in both academia and industry, are faced with challenges related to the development of efficient, feasible and ethical RCT designs as they focus on less toxic and more durable regimens for rheumatology patients with RA or PsA.

The ACR-FDA Summit was an interactive, consensus building format that brought together various stakeholders from academia and industry to provide a broad perspective on current clinical development challenges and offer practical means to overcome these challenges.